Biogen Inc. (BIIB) Earnings Call Transcript & Summary

April 29, 2026

NASDAQ US Health Care Biotechnology earnings 62 min

What were the key takeaways from Biogen Inc.'s April 29, 2026 earnings call?

In Q1 2026, Biogen Inc. reported total revenue of $2.5 billion, reflecting a 2% year-over-year increase, and a significant GAAP diluted EPS of $2.15, up 31% year-over-year. The company highlighted strong performance from its growth products, generating $851 million in revenue, a 12% increase, and maintained disciplined cost management while investing in its late-stage pipeline. Management reiterated confidence in the business outlook and maintained guidance, signaling a positive trajectory for the remainder of the fiscal year.

What topics did Biogen Inc. cover?

  • Strong Growth Products Performance: Biogen's growth products generated $851 million in revenue, up 12% year-over-year, with LEQEMBI leading the charge at $168 million, a 74% increase. Management noted, "the growth products are now generating $850 million in the first quarter, and that's up 12%."
  • High Dose SPINRAZA Launch: The launch of high-dose SPINRAZA is showing promise, with 20% of patients already submitting start forms for the new dosage. Management stated, "we do believe high dose now has a new opportunity for us, and we are seeing great interest in high dose from not just patients but also physicians."
  • Pipeline Developments: Biogen's pipeline is expected to deliver multiple data readouts starting this year, including pivotal studies for Salanersen and Litifilimab. Priya Singhal emphasized, "this year marks the start of a multiyear registrational data flow that includes multiple programs and extends through the end of the decade."
  • Apellis Acquisition Impact: The pending acquisition of Apellis is expected to enhance Biogen's growth portfolio and is projected to be accretive to EPS in 2027. Management noted, "we believe this transaction represents an attractive use of capital that will further bolster both our top line and bottom line growth prospects."
  • Cost Management and Financial Discipline: Biogen maintained a disciplined approach to costs, with non-GAAP core operating expenses at approximately $1.1 billion. Robin Kramer stated, "we maintained our cost discipline while supporting our late-stage pipeline development and product launches."

What were Biogen Inc.'s April 29, 2026 results?

  • Total Revenue: $2.5 billion (+2% YoY)
  • GAAP EPS: $2.15 (+31% YoY)
  • Non-GAAP EPS: $3.57 (+18% YoY)
  • LEQEMBI Revenue: $168 million (+74% YoY)
  • SKYCLARYS Revenue: $151 million (+22% YoY)
  • Free Cash Flow: $594 million

Biogen's Q1 2026 results indicate a solid recovery trajectory, driven by strong performance in growth products and a promising pipeline. The upcoming data readouts and the Apellis acquisition present potential catalysts for future growth, while execution risks and competitive pressures remain key areas to monitor.

Earnings Call Speaker Segments

Tim Power

executive
#1

Hi everyone, thanks for joining, and good morning — welcome to Biogen's call covering first quarter 2026 earnings. During this call, we'll be sharing forward-looking statements, and those come with risks and uncertainties that might make actual results differ materially from what those statements suggest. You can find a full list of risk factors in our SEC filings, and we urge you to take a look at them. Our earnings release, along with other documents tied to our results and the reconciliations between GAAP and non-GAAP figures we discuss today, are available in the Investors section of biogen.com; the slides for this call have also been posted to our website. On today's call, you'll hear from Chris Viehbacher, our President and Chief Executive Officer; Dr. Priya Singhal, who leads Development; and Robin Kramer, our Chief Financial Officer. For the Q&A portion, Alicia Alaimo, President of North America, will also be with us. After we share a few opening remarks, we'll go to Q&A, and so that we can address as many questions as possible, we ask that each of you please ask just one question. With that, I'll turn things over to Chris.

Chris Viehbacher

executive
#2

Thanks, Tim. Morning, everybody. We're off to a really solid start this year. Thinking back on where the company stood in 2023, we had just wrapped up 4 straight years where both revenue and profit fell. Since that point, we've largely managed to get the business steady. That has taken an enormous effort from all our teams. What's fascinating about this business is that simply shaving some costs won't get you there, and yes, we did need to remove some unnecessary cost. But a key part of what we've been doing is examining each individual line of the P&L and asking whether we're putting money behind growth. You have to make investments in this business. You can't save your way to prosperity. So there's been a great deal of careful consideration around how we fund growth, whether that's in research and development or on the commercial side. As Robin has mentioned before, we've actually moved a lot of costs around. Back in 2023, 90% of our commercial costs sat behind the MS portfolio. By moving that behind our growth products, one thing you can see on the first slide is that growth products are now bringing in $850 million in the first quarter, which is up 12%. And that 12% is actually a bit of an understatement, since SPINRAZA dipped somewhat. Now, SPINRAZA's decline was mostly due to shipment timing, plus there was a one-off event last year related to VAT, I believe, somewhere in Europe. But keep in mind, shipment timing matters a lot at Biogen. Of the 15,000 patients we treat with SPINRAZA each year, roughly 9,000 are outside the U.S., and in many countries we only ship once or twice annually, so it's naturally uneven. The good news is the new high dose SPINRAZA. As you've seen, it's now approved in the U.S., and we already have patients on the new dosing regimen. It's also already been approved in Japan, which was the first country to approve the high dose, and then Europe, and we're hearing a lot of positive feedback from those countries where it's launched. This won't just matter a great deal for competitiveness in a highly competitive area. We're also seeing some anecdotal reports of switch backs. In this market, with one of these devastating diseases, efficacy is truly paramount. I think the high dose really ought to give us an edge on the efficacy front here. So we're thrilled to see the growth products expanding like that. Turning to the big opportunity we have with LEQEMBI — as everyone is aware, much effort has gone into strengthening the care pathway over the several years since it launched, aiming to make things simpler for physicians as well as patients, and IQLIK is truly central to those efforts. During the past year, we secured approval for the maintenance indication, and you'll notice figures showing substantial patient numbers who, after completing the initial 18-month regimen to clear plaques, keep going and move into maintenance. For the induction subcutaneous, our PDUFA date is May 24, and once more we view this as a chance to smooth the care pathway, make things more convenient for patients, and strengthen how we compete against Gasuma. So that's the business — Biogen's business is performing well. And beyond that, we have the proposed pellet acquisition. The deal hasn't closed yet, so there's a limit on what we can discuss. Clearly, though, it broadens our commercial growth portfolio. Two marketed products are involved. Let me remind everyone that this is a single molecule, carrying 3 indications under 2 brands. As I've told many investors regarding SYFOVRE, there's this emphasis on ophthalmology. What I believe many people overlook is that geographic atrophy is genuinely an autoimmune disease, brought about when lesions form due to Averen immune activity. Our real aim with geographic atrophy is stopping these lesions from growing. So when the conversation turns to visual acuity, that's likely to be quite challenging, since the eye generally compensates around those lesions. The actual goal of treatment is halting disease progression, which has the potential to end in blindness. I think there's much work ahead in how we think about positioning this drug and identifying where its benefit lies. Empaveli delivers tremendous value for us. Our conviction in felzartamab grows stronger daily, and we're eager to see the first data, hoping those results will fulfill what we aspire to for this product. Yet if you rewind 6, 7 years, nephrology drew no interest; today, with the FDA having accepted proteinuria as a biomarker, many companies have entered this area. IGAM is clearly the largest market here, so when we consider recruitment for felzartamab and our prelaunch work, you discover there are plenty of companies recruiting in nephrology. I mean, Vertex, Vera, just to give a couple of examples — so inside the belly, plus bringing in the Appellate team, we've got an entire group set to go in nephrology, and we'll be in those nephrology offices, establishing those relationships, attending congresses at this point with a product on the market, not something still to come; so we have confidence both in Empaveli's growth, and in what that can deliver for an entire nephrology franchise at Biogen, and I have to say we're quite enthusiastic about it. And I think every one of the discussions we've had with the Apellis team ahead of a possible integration. I think there's — to begin with, there's remarkable talent in the Palace team. But I think it's also reasonable to say that inside Biogen, I think we can likely deliver additional resources to genuinely back those teams. And I don't foresee a major inflection in SYFOVRE, for instance, but I do think — there's a chance to grow that product. And I think, as I mentioned, Empaveli inside a wider nephrology franchise, that could transform the game for Biogen down the road; so as we consider this, — we do anticipate the acquisition will be accretive in 2027. And as you look forward across the coming years, this substantially lifts Biogen's EPS outlook. And if I move to the next chart here. Now don't pull out your micrometers and attempt to gauge these arrows here, this is intended to illustrate where we believe this is heading. If we simply take what Wall Street believes Biogen will do, I can't claim we'd be pleased with that, but that's what exists in the public domain. It's approximately flat through 2030. Now as you examine what appellate can do, this lets Biogen begin growing right now, that's our belief; and then the pipeline begins to read out. We have plenty of data readouts already beginning this year and back-to-back across the years; and as one investor told me, he said, I get this. previously we had a pipeline arriving on a flat business. Now I see a pipeline arriving on a growing business. And I think that's the essential distinction in what the Apellis acquisition delivers for us. And we're still going to keep doing business development. Through all of this, we just bought the China rights for felzartamab, that's a significant market for IgAN, but China is a large important market for us. And Biogen has been comparatively small in China. China ranks as the number two pharmaceutical market globally, so felzartamab and securing these rights — not solely obtaining global rights for PELSA, but truly establishing our operations in China as well; so once more, we keep putting money into growth, yet I believe many of those investments, much of the effort we've completed across the past 2, 3 years, is now paying off. And at minimum this is the vision; at this point we're quite aware that business 10% is strategy, execution. So as a team we must now deliver to bring all of this together, but at least this is the ambition we hold for our company; with that — let's discuss that pipeline, and I'll hand it over to Priya.

Priya Singhal

executive
#3

Thanks, Chris. From a development perspective, this quarter was a really strong one for Biogen, with significant strides made across both the products we market and our late-stage pipeline. On the left side of the slide, you're able to see how we've kept making headway in backing our commercialized portfolio. To begin with, the approval in the U.S. of high dose SPINRAZA marks a substantial step forward for those living with SMA and further cements Biogen's leadership position in that category. On top of that, in Alzheimer's disease, new real-world data for Leqembi reveal robust treatment persistence, with close to 80% of patients still on therapy at 18 months and nearly 70% at 2 years; in our view, these findings highlight how much importance patients and HCPs place on continued treatment of this progressive disease, going beyond simply reducing amyloid block. Now looking at the right side, we shared significant new data that bolster the promise of our late-stage, high conviction pipeline. Fresh findings from Salanersen show durable benefit across 1 year in children who had prior gene therapy, underscoring the potential for high efficacy with 1 yearly dosing. Notably, dosing of the first patient has now occurred in the pivotal STELLA-1 study, which is evaluating Salanersen in treatment-naive T-symptomatic infants. Simultaneously, we keep growing our confidence in Litifilimab, and there we presented positive Phase II data from the ongoing Phase II/III AMITA study in SLE. All of this headway strengthens how confident we are in our late-stage pipeline; and as this slide makes clear, we don't anticipate a long wait for that potential impact. This year kicks off a multiyear flow of registrational data spanning multiple programs and running through the end of the decade. As you also heard from Chris, we think these data will keep bolstering our growth outlook. And significantly, as was reflected previously, we have a number of data-related inflection points during 2026. As you're aware, we have a PDUFA date approaching for our Leqembi IQLIK initiation next month. We also have readouts from our pre-proof of concept pipeline, where we keep pioneering and tackling key scientific questions that might help patients. Our cycle of registrational readouts starts later this year. And across the next 18 months, we anticipate seeing SLE and CLE data from every Phase III study of Litifilimab, along with readouts from the first Phase III study of FELZARTAMAB in AMR and the Phase III study for ZOREVUNERSEN in Dravet syndrome. In my view, this is a very exciting period for the Biogen pipeline. I'd now like to hand the call over to Robin for an update on our financial performance.

Robin Kramer

executive
#4

Appreciate that, Priya. Let me begin by walking through the main highlights from a solid first quarter of 2026. We brought in total revenue of $2.5 billion, which is a 2% increase compared to the same period last year, alongside GAAP diluted EPS of $2.15, which rose 31% versus a year ago, and non-GAAP diluted EPS of $3.57, which climbed 18% year-over-year. It's encouraging to see our growth products keep delivering, bringing in $851 million of revenue, a 12% rise year-over-year. The revenue from our growth products, a group that includes VUMERITY, exceeded what we brought in from our remaining MS products during the first quarter of 2026. At the same time, we kept a tight grip on costs while funding our late-stage pipeline work and product launches, with non-GAAP core operating expenses of roughly $1.1 billion in the first quarter of 2026. That led to $594 million of free cash flow for the quarter, which lets us keep backing the business and put money into future growth, including the expected appellate transaction. We see that transaction as a capital allocation opportunity that should strengthen our prospects for growth on both the top line and bottom line, as well as therapeutic areas that fit with our immunology and rare disease strategy. I'll have more to say on that transaction shortly. Let me move now to how our revenue performed this quarter, beginning with our growth products. LEQEMBI market revenue reached $168 million in the first quarter of 2026, a 74% jump year-over-year. We continued to see sequential market growth across key markets such as the U.S., Japan and China; in China, uptake was strong in Q1, reflecting ongoing demand growth, and sequential revenue got a boost from finishing the drawdown of inventory in Q4 2025. By total patient share, LEQEMBI continues to lead the market in the U.S., Japan and China. — and we're looking ahead to next month's U.S. PDUFA date for IQLIK initiation. SKYCLARYS posted sequential growth in global patient demand, with first quarter 2026 global revenue of $151 million, which works out to 22% growth year-over-year; for SKYCLARYS, U.S. revenue took a hit from the inventory dynamics we talked about on the Q4 2025 call, with demand growing moderately. Beyond the U.S., demand keeps expanding as we carry on with our SKYCLARYS launch. SKYCLARYS can now be found in 35 countries, and our expectation remains that SKYCLARYS growth will be driven by ex U.S. as we keep advancing the launch. Let me now go over the highlights of our key P&L items for the quarter. Non-GAAP R&D expense came to $480 million in Q1 2026, and the year-over-year increase reflects investments in our Phase III clinical programs, among them felzartamab and Litifilimab, plus the phasing of spend within the year. Non-GAAP SG&A expense came to $600 million in Q1 2026, and the year-over-year increase reflects planned prelaunch activities supporting lupus and nephrology, direct-to-consumer advertising for VUMERITY and ZURZUVAE, and the phasing of spend within the year. GAAP and non-GAAP effective tax rates for the first quarter of 2026 were 15.4% and 15.3%, respectively. The year-over-year decline stemmed from favorable impacts from a foreign tax settlement and vesting of certain share-based awards, partly offset by the increase in U.S. The way foreign earnings get taxed in 2026 under the One Big Beautiful Bill app. And as we said before, we booked about $34 million of acquired IP R&D during the first quarter of 2026, mostly tied to our AltiGen and Alloy transaction, which worked out to roughly a $0.20 per share hit on both GAAP and non-GAAP EPS. Just to remind everyone, back in the first quarter of 2025 we booked $165 million of acquired IP R&D tied to the upfront payment to Therapeutics under our collaboration for ZOREVUNERSEN in Dravet syndrome treatment across every territory except the U.S., Canada, and Mexico, and that came to an impact of about $0.95 per share on GAAP and non-GAAP EPS; that solid commercial execution, together with disciplined financial management, produced ongoing strong free cash flow results. Free cash flow came to $594 million during the first quarter of 2026, and we finished the quarter holding $4.7 billion in cash and marketable securities along with $1.5 billion of net debt. Since the Apellis transaction should close during the second quarter of 2026, our plan is to finance it using $3.6 billion in cash off the balance sheet plus $2 billion in bank borrowings. Because we anticipate generating strong cash flow, we expect those $2 billion in new borrowings to be repaid before 2027 ends. Because the policy landscape keeps shifting, we've refreshed the slide we originally showed you at this point last year. Our view remains that the way our U.S. manufacturing footprint, supply chain, and overall business model are structured leaves us potentially more resilient against macroeconomic factors and policy uncertainty. Right now, looking at potential tariffs as announced so far, we don't anticipate a material impact on our business in 2026. This does not account for the pending Apellis acquisition. Now, moving to guidance. Our confidence in the underlying business's strength is just as high as it was when we gave guidance in February; we also still think it's important to invest in growth. On top of the roughly $0.20 EPS impact from the acquired IPR&D charges taken in Q1, we also anticipate $145 million, or an $0.80 EPS impact, of acquired IPR&D charges in the second quarter. More specifically, the TJ Bio transaction for felzartamab rights in China, which strengthens our nephrology franchise further and hands us worldwide rights to felzartamab, should account for $0.55 of that EPS impact. As Pria mentioned, we also got the first patient dosed in STELLAR 1, our pivotal Phase III Salanersen study, which triggered a milestone in the second quarter worth approximately $0.25 of EPS impact. Now for a few key points on this updated guidance. You'll notice our expected business outlook and underlying assumptions, our revenue outlook included, stayed consistent with prior guidance. As I noted earlier, we expect about $600 million of contract manufacturing revenue this year, phased with roughly 2/3 arriving in the first half. For the second quarter, we anticipate core operating expenses will be about the same as what we saw in Q1. Staying disciplined on costs continues to be our goal, even as we keep investing — which includes backing the programs we've been adding to our pipeline via business development. I'd ask that you take a look at this slide as well as our press release, since they contain other key assumptions behind our full year 2026 guidance. And last, I want to touch on a handful of items regarding what we anticipate from the Apellis transaction. Since that deal hasn't closed yet, we aren't offering consolidated guidance at this point. That said, once the transaction closes and we report our second quarter results, our plan is to give 2026 guidance that includes Apellis. What we can share right now is our belief that we'll be acquiring 2 best-in-class commercialized medicines that strengthen our growth portfolio. In our view, Syfovre and Empaveli will make a meaningful contribution to top line growth both near term and long term; on our non-GAAP and other income expense line, we anticipate an impact of roughly $120 million to $130 million during 2026, mostly from financing and foregone interest income; we also anticipate that the strong cash flow our combined businesses generate will give us the chance to delever by the end of 2027, and that non-GAAP EPS in 2027 will be accretive as a result of this transaction. Our view is that this deal is an appealing deployment of capital that will further strengthen our top line and bottom line growth prospects in therapeutic areas that fit with our immunology and rare disease strategy. With that said, I'll hand things back to Tim so we can begin taking questions.

Tim Power

executive
#5

Thanks, Robin. Can we go to our first question, please?

Brian Abrahams

analyst
#6

Congratulations on the quarter. When we think about the BIIB080 data that's coming up, I'd like to hear your current perspective on what sorts of signals you'd want to see in order to proceed. Also, to what extent would that be shaped by the possibility you anticipate for making the way it's given even better?

Chris Viehbacher

executive
#7

Priya?

Priya Singhal

executive
#8

Thank you, Brian. If we take a step back, what we have in BIIB080 is an antisense oligonucleotide. Its target is tau, and the goal is to lower it — and prior studies have shown us that going after this with an antibody from outside the cell simply hasn't delivered results; that's precisely where the ASO strategy stands apart. Our view is that it may be able to reach tau both inside and outside cells; in our Phase Ib, which was a small study, we did observe a decrease in tau, and that was quite encouraging, which is what pushed us toward conducting a proof-of-concept study. The Celia readout is going to provide that answer for us. Since this is ground-breaking work, what we hope to determine is whether bringing tau down translates into something clinically meaningful, particularly when it comes to cognition. While doing that, we are testing a number of dosing schedules and a number of treatment frequencies. So we'll be examining the data in its entirety; we anticipate having it at some point around the middle of the year, and I'd say our intention is to review it, then share it and present it at forthcoming forums. That's what we're planning.

Brian Abrahams

analyst
#9

What about the way it's dosed?

Priya Singhal

executive
#10

Right. Regarding how it's administered, I want to mention that from an Infratil standpoint, enrollment in the study happened quite fast. We understand that should this eventually become a medicine, we'd be evaluating alternative approaches. So we're exploring different delivery methods; those are currently in the preclinical and research stages, and as you're aware, we acquired Alceon not long ago, which provides us with an additional possible path to investigate should we keep moving forward with implicit delivery.

Andrew Tsai

analyst
#11

When we look ahead to what else could drive things in 2026, I wanted to ask specifically about LITIFILIMAB and how you're thinking about the filing approach. If both Phase III studies come back positive later this year, would you consider going straight to filing for SLE? Or would you hold off and file once the older do file 1 or 2 NDAs are submitted? And then, if only the SLE study hits that big endpoint while the other 1 is trending in the right direction, would you still go ahead and file in that SLE?

Priya Singhal

executive
#12

Thanks, Andrew; the potential of LITIFILIMAB has us excited. In SLE, we have 2 Phase III trials. Those should read out during this year, we sped up the second trial, and our CLE trial is going really well. That one should read out early next year. On the filing approach, we typically don't say much about it, though I would note that as things stand we view this as a package, and we'll share more once these studies kind of read out. As for the second part, if one trial looked positive and the other looked negative, I think, again, we'd be evaluating the totality of data, but precedence exists for that. with the other product in the field. So in our view, that alone wouldn't be a showstopper; we stay very encouraged and we're very pleased about the breakthrough designation LITIFILIMAB received for CLE earlier this year; and we also just presented data from a second Phase II that was positive in CLE. So we continue to be optimistic.

Geoff Meacham

analyst
#13

Chris, you said that even after Apellis, you're continuing to evaluate BD possibilities. Could you perhaps walk us through how you'd weigh outside innovation against investments, internal R&D, and SG&A? Clearly, following the appellate, you have to put money in to get that — to get the growth trajectory moving?

Chris Viehbacher

executive
#14

Yeah. So, thanks, Geoff. As we've previously stated, we feel — I believe we're feeling really positive regarding our late-stage pipeline. Lupus, I think, might become a fairly substantial franchise for us, since alongside LITIFILIMAB, we also have a partnership with UCB on dapirolizumab, and we have — we'll be taking the marketing lead in the U.S. and Japan. On that product. And naturally, we have a few other assets in early-stage development progressing for lupus. The entire nephrology franchise, I think, will also be fairly substantial for us. And then clearly, we have appellate. So when we consider BD, I'd say most of what we'll be concentrating on is early stage development and research, since that portion of the pipeline is fairly thin. We've bolstered that through a few collaborations, especially in immunology with Banca and Dara, for example, last year, and the partnership with Citi, plus there are a few others in there. So we're really trying to build the next generation of growth. I think if we execute well and we can bring everything and the pipeline does come through, this should be a company that can grow well into the 2030s. And what we truly need to be considering is what comes after that. So that's where, as I said, the early stage research stage pre-IND and perhaps Phase I is where the focus will be. Regarding M&A, we'd probably be more opportunistic. I don't think there's any specific need at that point to do that; but I suppose we'll keep watching, though we won't be doing the search. So across the last 2, 3 years, I mean, we've had a very systematic search and felt that we wanted to do M&A. I'd say with the Apellis transaction and with the pipeline, we don't see the same need to be as proactive on that front.

Michael Yee

analyst
#15

Let's return to BIIB080. Your team reduced the trial size from 700 patients. My understanding is you were aiming for roughly $400 million in the end, and what's the reason for trimming costs just to capture a signal? Could you remind us, keeping in mind that you want to be careful with spending, what kind of pattern would justify moving ahead, yet conversely, when the results arrive, if there isn't what you'd consider a genuinely compelling pattern, you'd presumably say so plainly and thereby tell the Street you have no plans to put money there. Perhaps give us more detail on this, Chris, or Priya, to help us grasp the disclosure side and how we ought to think it through.

Priya Singhal

executive
#16

Thank you, Mike. Taking a step back, indeed, when we first set up the CELIA trial, it had a bigger N, and the readout from our Phase Ib study, I believe, is what made us confident enough to recalculate the power for that trial and restructure it. Consequently, we have strong confidence that the study is properly configured to provide an answer as we genuinely put this highly significant hypothesis to the test, since tau reduction was already observed by us in Phase Ib, and at this point we seek the shift from tau reduction into clinical efficacy. As a quick note, CDR sum of boxes serves as the trial's primary endpoint, which, as you're aware, is a validated measure, though we are examining several doses along with 2 treatment paradigms, quarterly and also 6 monthly. Thus we will, once more, examine the whole picture to determine whether a clinical efficacy signal can be isolated. And I believe we will be extremely rigorous in our examination of it. What has truly shifted over the course of several years is that we now define our go/no-go criteria long before data readouts, and this particular readout is anticipated at midyear. So expect that we will scrutinize those results closely, while staying genuinely rigorous regarding the following step. since that is precisely the purpose of this proof of concept, if and how we advance to Phase III.

Chris Viehbacher

executive
#17

One thing that stands out as interesting, I'd say, is that once again, there simply isn't any prior example to follow, correct? And when it came to putting the study together, I believe it's fair to say we essentially examined what had been done with amyloid trials, correct? There's the 18-month follow-up we have. We're examining a comparable patient group since that's all we have knowledge of. So we're going to learn a tremendous amount from this study. Of course, you'd want to observe the proper decrease in tau, and tau PET findings are going to matter. And then clearly, can you detect any change when it comes to cognition? That would matter in order to move forward. Must that reach statistical significance? Must that hit a particular percentage? I believe that's where the full picture of information comes in — while we feel fairly confident about our ability to lower tau, nobody has any idea how long tau needs to be lowered before cognition improves. And — when you consider how plaque advances, its onset takes longer, whereas tau's onset is quicker. So we don't truly know precisely which patient group is the correct one. It could match amyloid, or it could be different. And that's the reason we've stated right from the beginning that this is a pioneering study. And we, along with the entire medical academic community, are going to gain knowledge from it. The threshold doesn't have to be particularly high, necessarily. But I think we do need to observe certain indications that provide us — clearly, optimism that a clinical benefit would result.

Salveen Richter

analyst
#18

Regarding LEQEMBI, can you bring us up to date on how blood-based biomarkers are being taken up and used, and are there patients who finished receiving some lower amount and then moved over to LEQEMBI maintenance?

Chris Viehbacher

executive
#19

Alisha, perhaps you'd like to handle that one?

Alisha Alaimo

executive
#20

Absolutely. Biomarker tests using blood have been expanding at nearly the same rate we witnessed previously across more than 20, and as we know, those saw extremely swift uptake. Even so, they generally weren't relied upon as the sole means of confirmation. That said, what we're observing is an ongoing PCP pilot — as you're aware, this involves Biogen and Eisai — and we already have preliminary signals from that pilot showing greater use of blood-based biomarkers among PCPs than among those without such a pilot in place. So this demonstrates that after education happens, they keep doing it increasingly. What's more significant is that CMS recently decided blood-based biomarkers are acceptable for confirmation when entered into their database, meaning that when you administer the drug, reimbursement becomes possible. I'm aware that during the previous year, this loomed large as a concern among physicians, and now that mechanism has been established. Therefore, in my view, going forward we'll witness blood-based biomarkers being relied on increasingly for confirmation relative to where they stand today. Uptake will be somewhat gradual, yet awareness is exceptionally elevated; thus I genuinely believe that the more they utilize it, test it, and experiment with it, the more it will serve confirmation purposes. As you shift toward something — regarding the question you posed about Casein during this initial quarter of the year, that's when you'd anticipate seeing the group of patients who began Cassina now reaching their 18-month point; consequently, during quarter 1 you'll observe those patients typically discontinuing the product, and that's when we begin receiving feedback. I can tell you that physicians are asking what should we do? — for certain patients. And if you examine market research, patients overall, regardless of which of the products they're on, wish to remain on product; there's apprehension about discontinuing and experiencing cognitive decline. We also have multiple accounts exploring ways to transition them to LEQEMBI — as you know, we can't supply data on that since we lack it — but we do have physicians investigating whether we can move them to maintenance or to subcu maintenance of LEQEMBI.

David Amsellem

analyst
#21

Let me start with a big-picture question about SYFOVRE, if you're able to address it. I realize the deal hasn't been finalized yet. Still, could you speak broadly about how the competitive landscape is shifting — especially regarding other therapies in development whose primary endpoints center on visual acuity rather than lesion burden? Help us grasp how you see SYFOVRE fitting into this changing picture, and in the end, what evidence you can cite about the product's effect on visual acuity.

Priya Singhal

executive
#22

Thank you, David. Taking a step back, SYFOVRE is approved for geographic atrophy. This condition is extremely common, irreversible, and progressive, and it results in blindness. The median duration, I believe, comes to roughly 6 to 6.5 years. Lesion growth has served as the gold standard for measuring efficacy. That's precisely where SYFOVRE delivers highly compelling results — a 42% statistically significant decrease in lesion growth. That was around the launch period. Since then, Apellis has additionally shared 5-year long-term findings demonstrating that progression can in fact be slowed by 1.5 years. Within that 6-year window, that is clearly quite meaningful. I completely agree there are competitive dynamics at play. Either way, the other product currently on the market goes after C5, which sits upstream of C3 — the target SYFOVRE addresses — and so far we have not observed that long-term information. Turning to what lies ahead competitively, it seems we're seeing additional programs aimed at C5 once more; that's one point. Another is that with Annexon, the Phase II results did not strike us as very convincing. In fact, it had no effect on geographic atrophy lesion growth, which in our view represents the gold standard. Chris noted that lesion growth truly matters to track, since eventually best corrected visual acuity would be affected. At the beginning, though, that isn't really the objective, because the eye compensates through peripheral vision. That's a key point to bear in mind. When we reviewed the Annexon data — clearly a very significant part of our diligence — we observed that BCVA for placebo actually declined substantially, so the drug arm appeared favorable, yet I think the jury is still out. As for Regeneron, I'm aware that's also competition, again targeting C5, and it's systemic as well as a combination. Our view is that they too are up against Syfovre, since it's directed at the eye and truly permits that tissue delivery, which we consider really important. And with Regeneron, proof of concept has yet to be established. So we'll await that. But we do know Soliris, with a quite similar mechanism of action, failed in Phase II in GA. There's certainly plenty to keep an eye on, in my view, yet we genuinely believe the IFB data make a strong case, and for us it will require an enormous undertaking across educational, medical, and scientific leadership to argue why treatment needs to happen now.

Chris Viehbacher

executive
#23

Absolutely, and from a business standpoint, the fact that SYFOVRE now has 5-year data really builds a kind of data fortress here. This is a disease that progresses slowly and steadily. And folks are looking for reassurance regarding safety and how things also evolve over time; so my sense is that it would take a very long while for any rival to actually produce a comparable volume of data, which will be required to give physicians and patients that confidence.

Paul Matteis

analyst
#24

Excellent. And congratulations on a fantastic quarter. If I could, a few more brief points regarding SYFOVRE. When it comes to considering what we'll spend on that franchise across the coming several years, how are you thinking right now, at minimum in a qualitative sense, about synergies and making use of existing capabilities, while also acknowledging the fact that GA might remain a market quite sensitive to promotion, one that could call for things such as ETC. And then perhaps just any brief perspective on the prefilled syringe — how optimistic are you, and how significant might that turn out to be?

Chris Viehbacher

executive
#25

So Alicia, you have a great deal of work in this area.

Alisha Alaimo

executive
#26

Yes, I'll respond to that. Thanks. To start, I'd mention that we've gotten together with a number of the executives at Apellis, and I have to say the impression that group and the leadership they truly possess has made on me is quite strong. A lot of those people have been in ophthalmology for a very long stretch and understand this area extremely well. So I'd say their performance has been strong and even tremendous, particularly in how they managed the vasculitis cases that emerged early on, and I believe they're doing a really fine job at present. When we examine this market and the possibilities within it, it's an extremely big one. As you're aware, it involves 1.5 million patients, and just 20% receive treatment. There's also a truly substantial unmet need among this patient population; moreover, this launch has delivered sustained growth in injections and in patient growth; thus we think there's a very large group of patients going untreated. Roughly 500,000 of them presently reside within those targeted physician offices that this team calls on today for GA. And based on what we've experienced, when you've got a product that slows progression, getting patients activated and building urgency among these HCPs matters enormously. So we recognize that going forward, we'll require careful education, highly effective messaging, and an explanation of why slowing this progression carries strong value; having said that, and knowing that clearly we don't — we haven't yet completed the deal. We recognize that getting these patients activated will be essential in this area, since when you walk in and make a request, generally you receive it. So we certainly know we'll be putting money toward DTC and TV ads, and as you're aware, they ran TV ads across 2 quarters, then halted them. I believe that's something we'd examine once the deal is closed, because educating these patients will be enormously important; we'll also be examining the messaging around how they can manage this within the office. We have no sense, entering this space, of how much time they've needed to devote to vasculitis as opposed to genuinely competing side by side in those offices. And third, I think our patient services will be a major benefit to them, along with this machine we've been fortunate enough to build across the last 7 years. If you truly step back and consider Biogen, particularly in North America, we've brought 7 products to market across the last 7 years in entirely different areas, which means we've built this dynamic engine capable of supporting launches throughout all the TAs we now hold. So in response to what you asked, our view is that we're going to uncover synergies, plus many of the skills housed at headquarters that we can offer them, which they perhaps haven't had the means to put money into. We'll additionally examine the places where their spending happens today, which we might shift toward other areas we think can fuel growth. And our analytics will be strong enough to determine which approaches they currently employ they consider effective, and which ones could be adjusted going forward. I'm also aware they may keep a wish list of items they would want to pursue, which perhaps they haven't yet carried out for the launch. So we intend to review every one of those items alongside them. and I believe that Apellis and Biogen, the two of them combined, will be far stronger than each on its own; and so I know my teams are eager to bring them into North America. And we're planning to provide a great deal of backing to the specialist SYFOVRE, so they feel they possess all they require to win in this space.

Mohit Bansal

analyst
#27

Congratulations on everything you've accomplished. I'd really like to get a sense of whether high-dose SPINRAZA, as a new option, aids with switching and persistence — do you believe it could steady the franchise or perhaps even drive growth now? I'm eager to hear your perspective on that.

Chris Viehbacher

executive
#28

Alisha, would you like to handle that one for North America?

Alisha Alaimo

executive
#29

Is the question specifically about SPINRAZA or SPINRAZA high dose?

Chris Viehbacher

executive
#30

High dose?

Alisha Alaimo

executive
#31

High dose. Alright, so to begin with, I should mention that I'm in the very same boardroom where, back when a patient advocacy group came in, I made a pitch to a few members of the executive committee, telling them patients had given us feedback that they wanted more. Then you jump ahead to now, and suddenly we've got SPINRAZA HD. So the first thing I'd say is this is one part of the business unlike anything I've witnessed over my whole career, where this patient community is intelligent and sharp; they know precisely what's launching, the timing of it, and they'll put in those asks before anything gets approved on the market. So if you consider what's taken place, SPINRAZA HD has only been available for under 1 month. I can tell you that 20% of the patients I cover have already submitted start forms so they can move to high-dose SPINRAZA. There are also patients coming over from competing products, plus patients adding it on top of Zolgensma. So for the U.S. organization in particular, I genuinely think high dose — with SPINRAZA we've had a fairly steady business up to now, and my team has performed superbly with SPINRAZA 12 mg — but we believe high dose presents a fresh opportunity for us now, and we're witnessing tremendous interest in high dose not only from patients but from physicians as well; so we've gotten off to a terrific start. Hundreds of start forms have come in, and I expect this will prove very favorable as we shift toward high-dose SPINRAZA and, ideally, someday Salanersen.

Robin Kramer

executive
#32

Possibly, Chris, I could address the situation outside the U.S. in much the same way. We received the green light for markets beyond America in Europe, and we're observing comparable momentum there, especially in Germany, where about 20% of patients are switching to the high dose. So the European rollout is off to a very solid start too.

Chris Viehbacher

executive
#33

If you look at high dose, you should also think about whether it might be able to take the place of the intrathecal injection that's on its way. And obviously, with Salanersen, Priya can report that we've now dosed the first patient in the Phase III trial. This is a franchise, I believe, that will prove durable and expand over time as we bring in these things that make it easier. When I travel to see our affiliates, I speak with physicians worldwide. Whenever they mention a patient who has come off SPINRAZA, you can always hear regret in the way they say it. Usually, the issue comes down to fatigue from intrathecal dosing, yet regret lingers since physicians regard this as the most effective treatment available. Now, in their eyes, the HD gives them an added rationale for championing that efficacy — plus, with the Alteon device, our hope is to remove part of that intrathecal fatigue. And once Salanersen arrives, it's anticipated to be given intrathecally just once a year, which ought to ease the administration side too; still, these are — the feeling you hear from doctors is remarkable. These are kids heading off to school today who, years ago, would not have survived. Biogen has developed some truly remarkable therapies, and this is one of them—it has made a major difference in health care, especially for children.

Evan Seigerman

analyst
#34

Congratulations on everything you've accomplished. I'd really like to dig a bit deeper into how well SKYCLARYS performed. Could you take me through what's behind that? I realize this product has had its ups and downs. Still, is this momentum something we ought to seriously factor in as the year goes on? And what would you say are the main things driving it?

Chris Viehbacher

executive
#35

Why don't you begin with the U.S., and after that we can discuss X.

Alisha Alaimo

executive
#36

Right, so regarding SKYCLARYS — what you observed for the quarter came in at $72 million year-over-year. Quarter-over-quarter, growth was 4%, and it was down. The reason it was down: inventory got built up at the end of Q4 last year, and then jumping ahead to Q1, when you count the buying weeks, Q1 contains 2 fewer than the quarter before. On patient demand, ours was exactly on par — the only issue was some lumpiness in inventory. The second point, though, just as a reminder for everybody, is where the U.S. stands at launch: we've reached the launch phase in which we're going out, we're deploying our patient finding, our next best action in the field, where each week our reps get a list of all the offices worth visiting, since we believe the patient is there, and then off they go on the hunt. That said, at this point most of our patients come from physicians who will write only one prescription ever for Friedreich's ataxia. Such patients are typically slower progressors, and they're considerably older than we had projected back when the product first launched. So locating them will require more time. The good news, however, is that we are locating them and they are starting on product, though from locating a patient to when they finally submit their script, time is required.

Robin Kramer

executive
#37

Outside the U.S., our quarterly revenue from SKYCLARYS actually came in higher than what we saw in the U.S. for the first time, as we keep executing on that launch. In Europe and beginning in Latin America; so from a demand standpoint, we do see demand rising outside the U.S.; and we expect that to keep going as the launches continue. And like I said earlier, it's already on the market in 35 countries.

Chris Viehbacher

executive
#38

When you look outside the United States, our approach is somewhat distinct. As Alisha mentioned, the key is locating the patients; once we identify them, we place them on the drug, and they participate in early access programs during the time we are negotiating reimbursement. Then, as reimbursement comes through, revenue will begin to appear all at once. It could be uneven, though, since we may move potentially several hundred patients simultaneously from generating 0 revenue to generating full revenue. At present, we not only have more revenue, but for a while now we have had more patients outside the U.S. who are on drugs and insight. As I just mentioned, they have not yet been fully reimbursed. That is happening gradually. And we are now witnessing the actual rollout and possible reimbursement in Latin America, for instance.

Alexandria Hammond

analyst
#39

Moving on to BIIB080 — what opportunities might exist in other telophase? And secondly, which biomarker will matter most when the Phase II data arrive, in terms of guiding what comes after Alzheimer's?

Priya Singhal

executive
#40

Thank you, and yes. We're exploring this question in considerable depth right now. The unmet need among primary tauopathies is something we recognize as substantial. From our Phase Ib trial, at least, the reduction we observed with BBA struck us as quite encouraging. What we'd want to see is tau reduction, along with additional specifics — things like which brain regions are involved — and that information would shape our approach regarding whether to pursue further efforts in primary tauopathies. Still, yes, it stays near the top of our list when it comes to evaluations and possible avenues.

Terence Flynn

analyst
#41

I’d like to ask about FELS and AMR. You highlighted buying the China rights for $100 million, plus some fairly large milestones tied to later performance. So I’m trying to understand what that says about the larger commercial opportunity, perhaps for both China and worldwide, and how you view it versus consensus.

Chris Viehbacher

executive
#42

Sure. When you consider kidney disease, many of these conditions have lacked therapies. There’s an entire alphabet soup here, correct? You have IC-MPGN, AMR, and PMN. There’s C3G too, and sometimes it’s difficult even to determine the epidemiology. For MPGN with Empaveli, I can say the true underlying epidemiology isn’t very clear; that makes it hard for investors, I think, to properly evaluate some of these. What we do know, for example, with the MR is that we simply assume roughly 11,000 patients. If you look at IgAN pricing, using the recent Otsuka price for IgAN of approximately $350,000 per year, the total addressable market comes to more than $2 billion, in fact somewhere from $2 billion to $3 billion, correct? And previously there was no treatment at all. Also, the Phase II data, though involving small numbers, demonstrated an impressive 80% resolution of AMR. Then there’s MDI, which is somewhat like a cousin to AMR. SP530023306 That brings in another 5,000 or 6,000 patients, and we have just started a trial in MVI. IgAN will clearly be a major market, especially across Asia. I believe there are 2 areas where we see competitiveness. Whenever you examine any autoimmune disease—and pre can address this better—you need to consider your position within the entire immune cascade. Usually, when treating an autoimmune disease, the goal is suppressing the immune system. Nobody wants to do that more than necessary. Therefore, having something near the actual cause of disease should matter; that’s why we believe CD38 offers a major advantage by acting on plasma cells and NK cells. The second area is treatment durability; in IgAN, our Phase II showed that following 9 infusions, treatment durability remained after 18 months. That suggests we may be doing something more disease-modifying than other agents; but Priya, since you’re far more expert on this than I am, you should probably comment here.

Priya Singhal

executive
#43

Chris, I'd say you hit all the key points. The initial data release for felzartamab has us genuinely enthusiastic. We're looking at 2027 for that. And honestly, taking a step back — what it does is go after the CD38 positive plasma cells. — in our view, those are a major origin of the disease-causing autoantibodies. Plus, that readout is a biopsy-based one, making it quite objective as well; so that has us excited.

Tim Power

executive
#44

Alright. I believe there's room for one final question. Perhaps this will be it, go ahead.

Jay Olson

analyst
#45

Nice work on the quarter. Could you discuss the real-world persistence with LEQEMBI in terms of treatment that was shared at ADPD — and how might the subcu form affect persistence going forward?

Priya Singhal

executive
#46

Thank you, Jay. Broadly speaking, there's a question — one that has persisted — about whether, once clearance of blocks is reduced, you keep patients on an anti-amyloid treatment, particularly one such as LEQEMBI, which targets both soluble toxic species and block reduction; we presented substantial data at earlier meetings regarding the advantages of maintaining patients on therapy. This, once more, is a progressive illness. When neurons die, they cannot be brought back. And we have demonstrated that fluid biomarkers return in under 6 months. After that, although the plant returns far more gradually. So that is one element. I believe the real-world evidence is persuasive, since it demonstrates that patients and neurologists genuinely wish to remain on therapy. That, to me, is a strong reflection of those findings. And this remains extremely, extremely significant for us. At present we are awaiting — we already have subcutaneous maintenance, which once again simplifies things and gives patients the option of staying on therapy; yet with subcutaneous initiation, where an FDA outcome is expected next month, we stay highly optimistic about how this might change the patient journey; and last, I will mention our presymptomatic trial of HEAD345, which is still set to read out in 2028; and we will see what that readout shows. We believe it will be a key landmark trial for the field; but what matters with subcutaneous being accepted is the possibility of interchangeability, which may be quite relevant among the presymptomatic population. So once again, we think this will be a highly important inflection point.

Tim Power

executive
#47

Appreciate that, Priya. And thank you, everyone, for being on today's call. We have additional questions, so please get in touch with me or <<inaudible>>. Thanks.

Operator

operator
#48

This concludes today's call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.